The prognosis predictive score around primary debulking surgery (PPSP) improves diagnostic efficacy in predicting the prognosis of ovarian cancer

Kawahara, Naoki; Kawaguchi, Ryuji; Waki, Keita; Maehana, Tomoka; Yamanaka, Satoshi; Yamada, Yoshiaki; Kimura, Fuminori

doi:10.1038/s41598-022-27333-1

Cited by 7 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on a few reports suggesting the usefulness of pretreatment peripheral WBC counts, this difference may help predict the prognosis. Our previous study showed that this difference contributes to the prognosis of ovarian cancer by comparing presurgical and postsurgical analyses [21,22]. This study rea rmed the usefulness of the differences in WBC counts in predicting recurrence.…”

Section: Discussionsupporting

confidence: 62%

Novel prognostic score for endometrial cancer

Maehana,

Kawahara,

Kamibayashi

et al. 2024

Preprint

View full text Add to dashboard Cite

Recently, there have been an increasing number of reports on the association between inflammatory markers and the prognosis of malignant tumors. However, the current indicators have limited accuracy. We aimed to develop a new scoring system for predicting endometrial cancer recurrence using inflammatory markers, tumor markers, and histological diagnosis. Patients with primary, previously untreated, and suspected endometrial cancer who underwent surgery at the Nara Medical University Hospital between January 2007 and December 2020 were included and followed up until March 2024. Items were divided into positive and negative using scores based on cutoff values and placed into the new scoring system, the endometrial tumor-related (ETR) score. We found that positive postoperative histological examination of lymph node metastasis and myometrial invasion, high levels of carcinoembryonic antigen and D-dimer in preoperative blood tests, and a large difference in preoperative and postoperative white blood cell counts were significantly associated with recurrence. The prediction of recurrence using the ETR score was superior to that using the International Federation of Gynecology and Obstetrics staging system, which is considered the best prognostic factor for survival. The ETR score is a significant prognostic marker of recurrence in patients who have undergone lymphadenectomy, with complete surgical tumor removal.

show abstract

Section: Discussionsupporting

confidence: 62%

Novel prognostic score for endometrial cancer

Maehana,

Kawahara,

Kamibayashi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, there have been studies on the association between tumor markers and cancer prognosis: CA125 is a prognostic tool for predicting relapse and progression of ovarian cancer; however, since CA125 is also known to be influenced by tumor histology and clinical stage, it remains controversial (33,34). Other studies have shown that pretreatment serum CA125 level is associated with disease progression of ovarian cancer (33)(34)(35). According to a previous study, serum CA19-9 levels >70.3 U/ml decrease the odds of survival in OCCC, whereas CA125 and HE4 levels do not (25).…”

Section: Discussionmentioning

confidence: 99%

Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer

Maehana,

Kawaguchi,

Nishikawa

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Tissue factor pathway inhibitor-2 (TFPI2) is a tumor marker for diagnosing ovarian cancer and ovarian clear cell carcinoma (OCCC); however, its effectiveness as a prognostic marker remains unclear. The present study aimed to investigate the utility of TFPI2 as a prognostic marker for ovarian cancer. A total of 256 cases of ovarian cancer was collected at Nara Medical University (Kashihara, Japan) from January 2008 to January 2022. The majority of cases were serous carcinoma (109, 42.6%), followed by OCCC (66, 25.8%), mucinous carcinoma (40, 15.6%), endometrial carcinoma (15, 5.9%), and other (26, 10.2%). The median preoperative serum TFPI2 for ovarian cancer was 219.0 (82.5–5,824.2) pg/ml. Overall survival (OS) of patients with non-OCCC and OCCC was calculated using the cut-off value determined obtained through receiver operating characteristic curve analysis. Cut-off values of TFPI2 for OS were 201 for non-OCCC and 255 pg/ml for OCCC. In univariate analysis, OS was significantly elevated in patients with non-OCCC and OCCC who had TFPI2 levels ≥201 pg/ml (P<0.001) and ≥255 pg/ml (P=0.036), respectively. Progression-free survival (PFS) was significantly elevated in patients with non-OCCC and OCCC who had TFPI2 levels ≥201 and ≥255 pg/ml (both P<0.001), respectively. Multivariate analysis revealed that OS was significantly higher in patients with non-OCCC who had TFPI2 levels ≥201 pg/ml (P=0.021), while PFS was significantly higher in patients with OCCC who had TFPI2 levels ≥255 pg/ml (P=0.020). These findings suggest that TFPI2 is a potential prognostic marker for ovarian carcinoma.

show abstract

“…Among several studies reported as predictive tools for PFS and OS in advanced EOC, at least to our knowledge, there is no prognostic scoring system taking into account preand post-NACT patients' data. We reported the scoring system named the prognosis predictive score around primary debulking surgery (PPSP) for progression-free survival (PFS), in which there were no patients shared in the current cohort [29]. This scoring system is effective to predict the patient's prognosis for those who underwent primary debulking surgery.…”

Section: Discussionmentioning

confidence: 99%

The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients

Kawahara,

Yamanaka,

Sugimoto

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Recent studies have shown that pretreatment inflammatory responses can predict prognosis. However, no reports have analyzed the combined effect of the inflammatory response with pre-treatment and post-neo adjuvant chemotherapy (NACT). This retrospective study aims to identify factors predicting prognosis and create a novel predictive scoring system. Methods: The study was conducted at our institution between June 2006 and March 2020. Demographic and clinicopathological data were collected from patients with advanced epithelial ovarian cancer who underwent neoadjuvant chemotherapy after sample collection by laparoscopic or laparotomy surgery, followed by interval debulking surgery. We created a scoring system, called the Predictive Prognosis Score around NACT (PPSN), using factors extracted from a receiver operating characteristic curve analysis. Univariate and multivariate analyses were conducted to assess the efficacy of PPSN in predicting progression-free survival and overall survival. Kaplan-Meier and log-rank tests were used to compare the PFS or OS rate. Results: Our study included 72 patients, with a cut-off value of four for the scoring system. Our analysis showed that high PPSN (≥4) significantly predicts poor prognosis. Moreover, CD3+ and CD8+ tumor-infiltrating lymphocytes with low PPSN (<4) showed higher aggregation than those with high PPSN (≥4) cases. Conclusion: Our study shows that PPSN could be a useful prognostic tool for advanced EOC patients who undergo NACT followed by IDS.

show abstract

The prognosis predictive score around primary debulking surgery (PPSP) improves diagnostic efficacy in predicting the prognosis of ovarian cancer

Cited by 7 publications

References 63 publications

Novel prognostic score for endometrial cancer

Novel prognostic score for endometrial cancer

Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer

The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients

Contact Info

Product

Resources

About